# PHARMACEUTICAL 2013

## Durect CORP
## Rank 4 of 218



# PHARMACEUTICAL 2013

## Durect CORP
## Rank 4 of 218

The relative strengths and weaknesses of Durect CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Durect CORP compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 137% points.The greatest weakness of Durect CORP is the variable Research and Development, reducing the Economic Capital Ratio by 8.3% points.

The company's Economic Capital Ratio, given in the ranking table, is 427%, being 207% points above the market average of 220%.

| Input Variable | Value in 1000 USD |
|---|---|
| Assets, Current | 36,355 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 6,435 |
| Liabilities, Current | 6,927 |
| Liabilities, Non-Current | 0 |
| Other Assets | 688 |
| Other Compr. Net Income | 1.0 |
| Other Expenses | 4,654 |
| Other Liabilities | 0 |
| Other Net Income | 144 |
| Other Revenues | 53,070 |
| Property and Equipment | 2,457 |
| Research and Development | 20,265 |
| Selling, General and Administrative Expense | 12,095 |

| Output Variable | Value in 1000 USD |
|---|---|
| Assets | 45,935 |
| Liabilities | 6,927 |
| Expenses | 37,014 |
| Revenues | 53,070 |
| Stockholders Equity | 39,008 |
| Net Income | 16,200 |
| Comprehensive Net Income | 16,200 |
| BaseVar | 71,546 |
| ECR before LimitedLiability | 383% |
| Economic Capital Ratio | 427% |